NCT03341754View on ClinicalTrials.gov

Trial to Evaluate the Safety, Immunogenicity, and Efficacy of Malaria Infection in Malaria Naïve Adults

PHASE1CompletedINTERVENTIONAL
Enrollment

52

Participants

Timeline

Start Date

September 15, 2018

Primary Completion Date

October 28, 2019

Study Completion Date

March 23, 2020

Conditions
Malaria
Interventions
BIOLOGICAL

D/ChAd63-CA

Priming Component (DNA) = NMRC-M3V-D-PfCA (D-CA) Vaccine Boosting Component = ChAd63-PfCA

BIOLOGICAL

D/ChAd63-CAT

Priming Component (DNA) = NMRC-M3V-D-PfCAT (D-CAT) Boosting Component = ChAd63-PfCAT

OTHER

Infectivity Control (IC) Group

Subjects will be exposed to bites of 5 Anopheles stephensi mosquitoes carrying infectious Pf sporozoites within a controlled clinical environment.

Trial Locations (2)

20889

NMRC Clinical Trials Center, Bethesda

20910

WRAIR, Silver Spring

Sponsors
All Listed Sponsors
collaborator

University of Oxford

OTHER

collaborator

Walter Reed Army Institute of Research (WRAIR)

FED

collaborator

United States Agency for International Development (USAID)

FED

collaborator

Naval Medical Research Center

FED

lead

U.S. Army Medical Research and Development Command

FED

NCT03341754 - Trial to Evaluate the Safety, Immunogenicity, and Efficacy of Malaria Infection in Malaria Naïve Adults | Biotech Hunter | Biotech Hunter